Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Chetanraj Bhamare"'
Autor:
Prasad S. Kulkarni, Chandrasekaran Padmapriyadarsini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, B.S. Garg, Nithya J. Gogtay, Muralidhar Tambe, Sanjay Lalwani, Kiranjit Singh, Renuka Munshi, Sushant Meshram, T.S. Selvavinayagam, Krishna Pandey, Devi Madhavi Bhimarasetty, S.R. Ramakrishnan, Chetanraj Bhamare, Abhijeet Dharmadhikari, Chandrashekhar Budhawant, Cyrille J. Bonhomme, Madhuri Thakar, Swarali N. Kurle, Elizabeth J. Kelly, Manish Gautam, Nivedita Gupta, Samiran Panda, Balram Bhargava, Cyrus S. Poonawalla, Umesh Shaligram, Dhananjay Kapse, Bhagwat Gunale
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTAZD1222 (ChAdOx1 nCoV-19) is a replication-deficient adenoviral vectored coronavirus disease-19 (COVID-19) vaccine that is manufactured as SII-ChAdOx1 nCoV-19 by the Serum Institute of India Pvt Ltd following technology transfer from Oxford U
Externí odkaz:
https://doaj.org/article/8b89a3e8f8ac470894c80a7c06493aa6
Autor:
Prasad S. Kulkarni, Bhagwat Gunale, Sunil Kohli, Sanjay Lalwani, Srikanth Tripathy, Sonali Kar, Sidram Raut, Praveen Kulkarni, Aditi Apte, Ashish Bavdekar, Hira Lal Bhalla, Joyce S. Plested, Shane Cloney-Clark, MingZhu Zhu, Raj Kalkeri, Melinda Pryor, Stephanie Hamilton, Madhuri Thakar, Ranga S. Sannidhi, Punjita Baranwal, Chetanraj Bhamare, Abhijeet Dharmadhikari, Manish Gupta, Cyrus S. Poonawalla, Umesh Shaligram, Dhananjay Kapse, COVOVAX-Booster Study Group
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-14 (2023)
Abstract Due to waning immunity following primary immunization with COVID-19 vaccines, booster doses may be required. The present study assessed a heterologous booster of SII-NVX-CoV2373 (spike protein vaccine) in adults primed with viral vector and
Externí odkaz:
https://doaj.org/article/9a552b8a78384202b575842720c27791
Autor:
Gagandeep Kang, Anand Lakhkar, Chetanraj Bhamare, Abhijeet Dharmadhikari, Jyoti Narwadkar, Arti Kanujia, Sajjad Desai, Bhagwat Gunale, Cyrus S. Poonawalla, Prasad S. Kulkarni
Publikováno v:
Vaccine: X, Vol 15, Iss , Pp 100362- (2023)
Background: ROTASIIL, an oral live attenuated bovine-human reassortant pentavalent rotavirus vaccine, was approved in 2017. This post-marketing surveillance (PMS) was conducted to collect real-world data on the safety of ROTASIIL in India. Methods: O
Externí odkaz:
https://doaj.org/article/68d73e768154412791e8f4285eecd9e7
Autor:
Gagandeep Kang, Anand Lakhkar, Chetanraj Bhamare, Abhijeet Dharmadhikari, Jyoti Narwadkar, Arti Kanujia, Dhananjay Kapse, Bhagwat Gunale, Cyrus S. Poonawalla, Prasad S. Kulkarni
Publikováno v:
The Lancet Regional Health - Southeast Asia, Vol 14, Iss , Pp 100207- (2023)
Summary: Background: A vero cell-based inactivated Rabies Vaccine (Rabivax-S) and Rabies Human Monoclonal Antibody (Rabishield) have been approved since 2016. A post-marketing surveillance was conducted in India from 2020 to 2021 to gather real world
Externí odkaz:
https://doaj.org/article/b9f54205b1424c39b6a29ce58950f316
Autor:
Prasad S. Kulkarni, Abhijit Kadam, Sheela Godbole, Varsha Bhatt, Abhishek Raut, Sunil Kohli, Santanu Tripathi, Praveen Kulkarni, Rakhi Ludam, Madhav Prabhu, Ashish Bavdekar, Nithya J. Gogtay, Sushant Meshram, Tamilarasu Kadhiravan, Sonali Kar, D.H. Ashwath Narayana, Clarence Samuel, Govind Kulkarni, Abhay Gaidhane, Dipu Sathyapalan, Sidram Raut, Vijay Hadda, Hira Lal Bhalla, Chetanraj Bhamare, Abhijeet Dharmadhikari, Joyce S. Plested, Shane Cloney-Clarke, Mingzhu Zhu, Melinda Pryor, Stephanie Hamilton, Madhuri Thakar, Ashwini Shete, Manish Gautam, Nivedita Gupta, Samiran Panda, Umesh Shaligram, Cyrus S. Poonawalla, Balram Bhargava, Bhagwat Gunale, Dhananjay Kapse, Shubhangi A. Kanitkar, Arjun L. Kakrani, Srikanth P. Tripathy, Abhijit V. Tilak, Akshay A. Dhamne, Shahzad Beg Mirza, Prachi V. Athavale, Mandakini Bhowmik, Parag J. Ratnakar, Subodh Gupta, Vijayshri Deotale, Jyoti Jain, Ashwini Kalantri, Vineet Jain, Nidhi Goyal, Alok Arya, Temsunaro Rongsen-Chandola, Shreyasi Dasgupta, Pratibha Periera, Vanmathi A, Anand Kawade, Arunkumar Gondhali, Palvi Kudyar, Abhishek Singh, Ravi Yadav, Alina Alexander, Venugopalan Gunasekaran, Sekar Dineshbabu, P.C. Samantaray, H.S. Ravish, Deepshikha Kamra, Shilpa Gaidhane, Quazi Syed Zahiruddin, Merlin Moni, Anil Kumar, Ameet Dravid, Anant Mohan, Tejas Suri, Tejas K. Patel, Surekha Kishore, Rahul Choche, Deepak Ghatage, Sugam Salvi
Publikováno v:
The Lancet Regional Health - Southeast Asia, Vol 10, Iss , Pp 100139- (2023)
Summary: Background: NVX-CoV2373, a Covid-19 vaccine was developed in the USA with ∼90% efficacy. The same vaccine is manufactured in India after technology transfer (called as SII-NVX-CoV2373), was evaluated in this phase 2/3 immuno-bridging study
Externí odkaz:
https://doaj.org/article/82d9dafd89e042aabbf3940c237b71b1
Autor:
Prasad Kulkarni, Bhagwat Gunale, Sunil Kohli, Sanjay Lalwani, Srikanth Tripathy, Sonali Kar, Sidram Raut, Praveen Kulkarni, Aditi Apte, Ashish Bavdekar, Hira Lal Bhalla, Joyce Plested, Shane Cloney-Clark, MingZhu Zhu, Raj Kalkeri, Melinda Pryor, Stephanie Hamilton, Madhuri Thakar, Ranga Sannidhi, Punjita Baranwal, Chetanraj Bhamare, Abhijeet Dharmadhikari, Manish Gupta, Cyrus Poonawalla, Umesh Shaligram, Dhananjay Kapse
Background Due to waning immunity following primary immunization with Covid-19 vaccines, booster doses may be required. The present study assessed a heterologous booster of SII-NVX-CoV2373 (spike protein vaccine) in adults primed with viral vector an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e1d8dda429148041d004f010f7efa2b
https://doi.org/10.21203/rs.3.rs-2549560/v1
https://doi.org/10.21203/rs.3.rs-2549560/v1
Autor:
Prasad S. Kulkarni, Abhijit Kadam, Sheela Godbole, Varsha Bhatt, Abhishek Raut, Sunil Kohli, Santanu Tripathi, Praveen Kulkarni, Rakhi Ludam, Madhav Prabhu, Ashish Bavdekar, Nithya J. Gogtay, Sushant Meshram, Tamilarasu Kadhiravan, Sonali Kar, Ashwath Narayana, Clarence Samuel, Govind Kulkarni, Abhay Gaidhane, Dipu Sathyapalan, Sidram Raut, Vijay Hadda, Hira Lal Bhalla, Chetanraj Bhamare, Abhijeet Dharmadhikari, Joyce Plested, Shane Cloney-Clarke, Mingzhu Zhu, Melinda Pryor, Madhuri Thakar, Ashwini Shete, Manish Gautam, Nivedita Gupta, Samiran Panda, Umesh Shaligram, Cyrus Poonawalla, Balram Bhargava, Bhagwat Gunale, Dhananjay Kapse, for the COVOVAX Study Group
Publikováno v:
SSRN Electronic Journal.
Autor:
Prasad S. Kulkarni, Chandrasekaran Padmapriyadarshini, Johan Vekemans, Ashish Bavdekar, Madhu Gupta, Praveen Kulkarni, B. S. Garg, Nithya J. Gogtay, Muralidhar Tambe, Sanjay Lalwani, Kiranjit Singh, Renuka Munshi, Sushant Meshram, T. S. Selvavinayagam, Krishna Pandey, Devi Madhavi Bhimarasetty, S. R. Ramakrishnan, Chetanraj Bhamare, Abhijeet Dharmadhikari, Rajeev Vadakkedath, Cyrille J. Bonhomme, Madhuri Thakar, Swarali N. Kurle, Elizabeth J. Kelly, Manish Gautam, Nivedita Gupta, Samiran Panda, Balram Bhargava, Umesh Shaligram, Dhananjay Kapse, Bhagwat Gunale, COVISHIELD Study Group
Publikováno v:
SSRN Electronic Journal.
Background: ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant) (SII-ChAdOx1 nCoV-19), manufactured in India at Serum Institute of India Pvt Ltd (SIIPL) after technology transfer from AstraZeneca, was evaluated in this phase 2/3 immunobridging study.
Autor:
Chetanraj Bhamare, S. R. Ramakrishnan, Madhu Gupta, Prasad S. Kulkarni, Nithya J Gogtay, Bishan S Garg, Madhuri Thakar, Sanjay Lalwani, Swarali N. Kurle, Dhananjay Kapse, Cyrille J. Bonhomme, Devi Madhavi Bhimarasetty, Renuka Munshi, Sushant H. Meshram, Johan Vekemans, Praveen Kulkarni, Bhagwat Gunale, Abhijeet Dharmadhikari, Manish Gautam, Krishna Pandey, Muralidhar Tambe, Chandrasekaran Padmapriyadarsini, Elizabeth J. Kelly, Ashish Bavdekar, Kiranjit Singh, Umesh Shaligram, Nivedita Gupta, Samiran Panda, T. S. Selvavinayagam, Rajeev Vadakkedath, Balram Bhargava
Publikováno v:
EClinicalMedicine
Background This phase 2/3 immunobridging study evaluated the safety and immunogenicity of the ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant) (SII-ChAdOx1 nCoV-19), manufactured in India at the Serum Institute of India Pvt Ltd (SIIPL), following te
Autor:
K. Anil, Abhijeet Dharmadhikari, Jaya Patel, R.L. Madhusudhan, Sajjad Desai, Prasad S. Kulkarni, Chetanraj Bhamare
Publikováno v:
Vaccine. 36(12)
Background Rotavirus Gastroenteritis (RVGE) is an important global public health problem. Recently a Lyophilized Pentavalent Human Bovine Reassortant Rotavirus vaccine (BRV-PV, Rotasiil) was licensed in India. A Liquid formulation of the same vaccine